The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

Experts at the 2025 ICE-T Symposium discussed the need for improved management of toxicities in patients with leukemia.

Roxadustat’s developers intend to file the full phase 3 protocol to the FDA in the fourth quarter of 2025.

A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.

“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as in solid tumors and beyond, includes immune therapies.

START is the largest early-phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, PhD, MRCPI.

Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple...